GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Yu Sunakawa (Japan) provides the highlights on cancer of the liver, small intestine and pancreas tract.
GI CONNECT has summarised the highlights from the ASCO GI 2020 meeting for you. Dr Yu Sunakawa (Japan) provides the highlights on cancer of the liver, small intestine and pancreas tract.
Dr Yu Sunakawa is a medical oncologist at St. Marianna University, Japan and previously worked as an instructor at Showa University Northern Yokohama Hospital in Yokohama, Japan. He also completed postdoctoral research fellowship training at University of Southern California/Norris Comprehensive Cancer Center in United States. In 2011, Dr Sunakawa received the board certification of the Japanese Society of Medical Oncology. Dr Sunakawa’s research interests are the identification and determination of molecular markers in cancerous tissues or blood that could predict cancer risk and clinical outcome in gastrointestinal cancer. He is also focusing on research regarding tumour immunity and received a Merit Award from the American Society of Clinical Oncology in 2014, for the research of genetic variations in immune checkpoint-related genes.
Bayer, Bristol-Myers, Biopharma, Chugai Pharm, Daiichi-Sankyo, Gurdant, Lilly, Ono Pharm, Sanofi, Sysmex, Takeda and Tahio Pharm.
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast
How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?
Understanding the role of molecular subtypes in guiding treatment selection
Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.